Through a partnership with United States-based company Angioblast Systems, Inc., Mesoblast is also developing treatments using adult stem cells for cardiac and vascular diseases, as well as for other degenerative conditions.

Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and rapid and successful completion of pre-clinical and clinical milestones required to achieve product marketing approval from the US Food and Drug Administration (FDA), Australian Therapeutic Goods Administration (TGA), and other international regulatory bodies.

Mesoblast has acquired a 33.3% equity in Angioblast, and has also acquired a worldwide licence to use the MPC technology for all orthopaedic indications.